在人类面板中设计具有低免疫原性的药物样抗体
Drug-like antibodies with low immunogenicity in human panels designed with Latent-X2
AI总结:
Latent-X2通过零样本设计生成具有强结合亲和力、药物样性质和低免疫原性的抗体,展示了无需AI基础设施即可实现的从头分子设计的治疗可行性。
摘要:
药物发现长期以来一直在寻找能够直接设计出药物样分子的计算系统:从一开始就具有开发性和非免疫原性。在这里,我们介绍了Latent-X2,这是一种前沿的生成模型,通过零样本设计具有强结合亲和力、药物样性质以及首次在任何从头生成的抗体中确认在人类供体面板中具有低免疫原性的抗体来实现这一目标。Latent-X2是一个全原子模型,条件于目标结构、表位指定和可选的抗体框架,同时生成序列和结构,同时建模结合的复合物。在每种模态中,仅测试4到24个设计,我们成功地生成了针对18个评估目标中的9个的VHH和scFv抗体,实现了50%的目标级别成功率,结合亲和力从皮摩尔到纳摩尔。设计的分子表现出与批准的抗体药物相匹配或超过的开发性特征,包括表达产量、聚集倾向、多反应性、疏水性和热稳定性,无需优化、筛选或选择。在任何AI生成抗体的第一个免疫原性评估中,代表性从头生成的VHH结合体针对TNFL9显示出在T细胞增殖和细胞因子释放实验中均具有强靶点结合和低免疫原性。该模型超越了抗体:针对长期以来被认为难以成药的K-Ras,我们生成了与万亿规模mRNA显示筛子竞争的宏循环肽结合体。这些性质直接来自模型,证明了零样本分子设计的治疗可行性,现在可在https://platform.latentlabs.com上无需AI基础设施或编程专业知识即可使用。
英文摘要:
Drug discovery has long sought computational systems capable of designing drug-like molecules directly: developable and non-immunogenic from the start. Here we introduce Latent-X2, a frontier generative model that achieves this goal through zero-shot design of antibodies with strong binding affinities, drug-like properties, and, for the first time for any de novo generated antibody, confirmed low immunogenicity in human donor panels. Latent-X2 is an all-atom model conditioned on target structure, epitope specification, and optional antibody framework, jointly generating sequences and structures while modelling the bound complex. Testing only 4 to 24 designs per target in each modality, we successfully generated VHH and scFv antibodies against 9 of 18 evaluated targets, achieving a 50% target-level success rate with picomolar to nanomolar binding affinities. Designed molecules exhibit developability profiles that match or exceed those of approved antibody therapeutics, including expression yield, aggregation propensity, polyreactivity, hydrophobicity, and thermal stability, without optimization, filtering, or selection. In the first immunogenicity assessment of any AI-generated antibody, representative de novo VHH binders targeting TNFL9 exhibit both potent target engagement and low immunogenicity across T-cell proliferation and cytokine release assays. The model generalizes beyond antibodies: against K-Ras, long considered undruggable, we generated macrocyclic peptide binders competitive with trillion-scale mRNA display screens. These properties emerge directly from the model, demonstrating the therapeutic viability of zero-shot molecular design, now available without AI infrastructure or coding expertise at https://platform.latentlabs.com.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。